Supernus (SUPN) announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically ...
(RTTNews) - Shares of Supernus Pharmaceuticals Inc. (SUPN) are down over 20% in premarket trading Wednesday, following disappointing results from a Phase 2b study of SPN-820 in adults with ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
3d
GlobalData on MSNSupernus’s stock sinks after depression drug fails trialSupernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...
Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...
Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results